Our laboratory has established various experimental haploidentical hematopoietic cell transplantation (HHCT) models and is studying novel conditioning regimens and agents that can be applied following transplantation to limit graft versus host disease (GvHD) while permitting donor chimerism, immune reconstitution and graft versus tumor effects. The mechanisms of action of these regimens are been investigated in leukemia and solid tumor models. Our objective is the translation of innovative HHCT approaches into Phase I/II trials for pediatric and adult patients with advanced hematologic malignancies and refractory solid tumors.

Zeng Y, Stokes J, Hahn S, Hoffman E, Katsanis E.  Activated MHC-mismatched T helper-1 lymphocyte infusion enhances graft-versus-leukemia with limited graft-versus-host disease. Bone Marrow Transplant 2014 Aug;49(8):1076-83.  Epub 2014 Apr 28. PMID: 24777185